Four-month landmark analysis for OS
| Immune variable* . | n . | HR (95% CI) . | P . |
|---|---|---|---|
| ALC | 93 | 0.20 (0.08-0.51)† | .004 |
| CD3+ T cells | 93 | 0.41 (0.24-0.71)† | .006 |
| CD4+ T cells | 93 | 0.43 (0.25-0.73)† | .006 |
| CD4+CD45RA+ T cells | 93 | 1.03 (0.70-1.51) | .887 |
| CD8+ T cells | 93 | 0.86 (0.60-1.24) | .434 |
| NK cells | 91 | 0.71 (0.32-1.60) | .420 |
| B cells | 93 | 0.80 (0.66-0.97) | .029 |
| PHA | 89 | 0.43 (0.26-0.71)† | .008 |
| Immune variable* . | n . | HR (95% CI) . | P . |
|---|---|---|---|
| ALC | 93 | 0.20 (0.08-0.51)† | .004 |
| CD3+ T cells | 93 | 0.41 (0.24-0.71)† | .006 |
| CD4+ T cells | 93 | 0.43 (0.25-0.73)† | .006 |
| CD4+CD45RA+ T cells | 93 | 1.03 (0.70-1.51) | .887 |
| CD8+ T cells | 93 | 0.86 (0.60-1.24) | .434 |
| NK cells | 91 | 0.71 (0.32-1.60) | .420 |
| B cells | 93 | 0.80 (0.66-0.97) | .029 |
| PHA | 89 | 0.43 (0.26-0.71)† | .008 |
P values significant at the .01 level are indicated in bold.
In univariable analysis of patient, graft, and posttransplant variables, only recipient age was significantly associated with OS (HR, 2.21 [95% CI, 1.31-3.75] per decade, P = .001). Patient sex, diagnosis, CMV seropositivity, engrafting CB unit–recipient HLA match, engrafted CB unit infused viable CD34+ and CD3+ cell doses, addition of haploidentical CD34+ cells, and day 100 aGVHD grade were not significant.
HR adjusted for age.